levodopa has been researched along with metallothionein in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asanuma, M; Furuta, H; Miyazaki, I; Ogawa, N; Sogawa, CA; Sogawa, N | 1 |
| Asanuma, M; Hozumi, H; Miyazaki, I; Miyoshi, K; Sogawa, N | 1 |
2 other study(ies) available for levodopa and metallothionein
| Article | Year |
|---|---|
Antioxidants protect against dopamine-induced metallothionein-III (GIF) mRNA expression in mouse glial cell line (VR-2g).
Topics: Adrenergic Agents; Adrenergic alpha-Agonists; Animals; Antioxidants; Ascorbic Acid; Cell Line; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Glutathione; Glycerol-3-Phosphate Dehydrogenase (NAD+); Glycerolphosphate Dehydrogenase; Levodopa; Metallothionein; Mice; Neuroglia; Norepinephrine; Oxidopamine; Protein Isoforms; Receptors, Dopamine D1; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vitamin E | 2000 |
Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicity.
Topics: Animals; Cell Line; Cytoprotection; Dopamine; Dopamine Agents; Levodopa; Metallothionein; Mice; Mice, Knockout; Oxidopamine; Parkinson Disease, Secondary; RNA, Messenger; Zinc | 2007 |